Mazdutide (also known as IBI362) is an innovative dual agonist targeting GLP-1 and glucagon receptors, developed for the treatment of obesity, type 2 diabetes, and related metabolic disorders. As a new-generation peptide drug, Mazdutide offers a powerful combination of weight reduction, glycemic control, and lipid regulation in one formulation.
Key Advantages:
-
Dual Mechanism of Action: Simultaneously activates GLP-1 and glucagon receptors to enhance metabolic effects.
-
Effective Weight Loss: Promotes satiety and increases energy expenditure, aiding in long-term weight control.
-
Improved Glucose & Lipid Metabolism: Demonstrated benefits in lowering blood sugar and improving lipid profiles.
-
Once-Weekly Dosing: Designed for convenient and sustained therapeutic effect with fewer injections.
Applications:
-
Obesity and Overweight Management
-
Type 2 Diabetes Treatment
-
Pharmaceutical R&D and Clinical Trials
